Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them una ... Read more >
Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stoppi ... Read more >
Status: Enrolling
Investigator: Lawrence Rice
Study Coordinator: Erin Webb
Phone: 713.441.1111
To purpose of this study is to assess safety and efficacy of BAX 930 in the prevention and treatment of acute episodes of thrombotic thrombocytopenic purpura (TTP) in subjects with severe hereditary deficiency of ADAMTS13 (cTTP; defined as plasm ... Read more >
Status: Open Not Enrolling
Investigator: Lawrence Rice
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
Study AG348-C-006 will evaluate the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase deficiency (PKD), who are not regularly receiving blood transfusions. Participants will be random ... Read more >
Status: Open Not Enrolling
Investigator: Jasleen Randhawa
Study Coordinator:
Phone:
Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >
Status: Open Not Enrolling
Investigator: Alpesh Shah
Study Coordinator:
Phone:
This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and OUS. A minimum of 40% of total patients will be enrolled in the US. This study will enroll patient ... Read more >
Status: Enrolling
Investigator: Jasleen Randhawa
Study Coordinator: Erick Villarreal-Williams
Phone: 346.238.5594
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibod ... Read more >
Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5263
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remissi ... Read more >